Table Graph
      published meta-analysis   sensitivity analysis   studies

tocilizumab in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMARIPOSA, 2021 (REV) 0.70 [0.21; 2.37] Rashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 (REV) 2.86 [1.36; 6.01] 2.06[0.99; 4.32]MARIPOSA, 2021 (REV), Rashad, 2021, Rashad, 2021 (REV)354%395seriousnot evaluable deathsdetailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 (REV) 2.17 [1.14; 4.14] 2.17[1.38; 3.41]Rashad, 2021, Rashad, 2021 (REV)20%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 (REV) 2.17 [1.14; 4.14] 2.17[1.38; 3.41]Rashad, 2021, Rashad, 2021 (REV)20%298seriousnot evaluable hospital dischargedetailed resultsMARIPOSA, 2021 (REV) 1.14 [0.72; 1.82] 1.14[0.72; 1.82]MARIPOSA, 2021 (REV)10%NAnot evaluable mechanical ventilationdetailed resultsMARIPOSA, 2021 (REV) 1.14 [0.48; 2.71] 1.14[0.48; 2.71]MARIPOSA, 2021 (REV)10%97NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-13 23:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons